Left sylvian subarachnoid neurocysticercosis: a therapeutic challenge
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.163.1865Keywords:
Neurocysticercosis, Taenia solium, Albendazole, Seizures, Blotting WesternAbstract
Introduction: Neurocysticercosis is a disease with high neurological morbidity, where subarachnoid subtype is a severe form. Secondary vasculitis is rare, but it can cause a stroke. The diagnosis is made by serology with enzyme-linked immunotransfer blot (ELIB) and tomography or resonance images with 3D sequence. Treatment is mainly medical. Case of report: A 28-year-old male with headache, expression aphasia and dysarthria. The images show a left frontal stroke, as well as a non-viable left temporal cyst and another viable left sylvian lesion, with positive ELIB. He was treated with clinical improvement. At 8 months, imaging control was performed due to new stroke. We saw reduction in size of the lesions, but still positive ELIB, so medical treatment was restarted with slow improvement of symptoms. Conclusion: Subarachnoid neurocysticercosis is a complex pathology, which requires multidisciplinary treatment, mainly medical, with difficult adherence to it due to its prolonged duration.
Downloads
Metrics
References
White AC, Garcia HH. Updates on the management of neurocysticercosis: Curr Opin Infect Dis. 2018;31(5):377-382. doi:10.1097/QCO.0000000000000480
Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg. 2010;8(2):100-104. doi:10.1016/j.ijsu.2009.12.006
Ou S wu, Wang J, Wang Y jie, Tao J, Li X guo. Microsurgical management of cerebral parenchymal cysticercosis. Clin Neurol Neurosurg. 2012;114(4):385-388. doi:10.1016/j.clineuro.2011.11.029
White AC, Coyle CM, Rajshekhar V, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66(8):e49-e75. doi:10.1093/cid/cix1084
Debacq G, Moyano LM, Garcia HH, et al. Systematic review and meta-analysis estimating association of cysticercosis and neurocysticercosis with epilepsy. Flisser A, ed. PLoS Negl Trop Dis. 2017;11(3):e0005153. doi:10.1371/journal.pntd.0005153
Ndimubanzi PC, Carabin H, Budke CM, et al. A Systematic Review of the Frequency of Neurocyticercosis with a Focus on People with Epilepsy. Preux PM, ed. PLoS Negl Trop Dis. 2010;4(11):e870. doi:10.1371/journal.pntd.0000870
Levy SA, Lillehei KO, Rubinstein D, Stears JC. Subarachnoid Neurocysticercosis with Occlusion of the Major Intracranial Arteries: Case Report: 183. Neurosurgery. 1995;36(1):183-188. doi:10.1227/00006123-199501000-00025
Rodriguez-Carbajal J, Del Brutto OH, Penagos P, Huebe J, Escobar A. Occlusion of the middle cerebral artery due to cysticercotic angiitis. Stroke. 1989;20(8):1095-1099. doi:10.1161/01.STR.20.8.1095
Vitosevic Z, Cetkovic M, Vitosevic B, Jovic D, Rajkovic N, Milisavljevic M. Blood supply of the internal capsule and basal nuclei. Srp Arh Celok Lek. 2005;133(1-2):41-45. doi:10.2298/SARH0502041V
Eddi C, Nari A, Amanfu W. Taenia solium cysticercosis/taeniosis: potential linkage with FAO activities; FAO support possibilities. Acta Trop. 2003;87(1):145-148. doi:10.1016/S0001-706X(03)00037-8
Sáenz B, Ramírez J, Aluja A, et al. Human and porcine neurocysticercosis: differences in the distribution and developmental stages of cysticerci: Human and porcine neurocysticercosis. Trop Med Int Health. 2008;13(5):697-702. doi:10.1111/j.1365-3156.2008.02059.x
García HH, Evans CAW, Nash TE, et al. Current Consensus Guidelines for Treatment of Neurocysticercosis. Clin Microbiol Rev. 2002;15(4):747-756. doi:10.1128/CMR.15.4.747-756.2002
Coyle CM, Mahanty S, Zunt JR, et al. Neurocysticercosis: Neglected but Not Forgotten. Engels D, ed. PLoS Negl Trop Dis. 2012;6(5):e1500. doi:10.1371/journal.pntd.0001500
O’Neal SE, Flecker RH. Hospitalization Frequency and Charges for Neurocysticercosis, United States, 2003–2012. Emerg Infect Dis. 2015;21(6):969-976. doi:10.3201/eid2106.141324
Webb CM, White AC. Update on the Diagnosis and Management of Neurocysticercosis. Curr Infect Dis Rep. 2016;18(12):44. doi:10.1007/s11908-016-0547-4
Dhawan N, Nijhawan R, Pandit S, Kaur P, Dhiman P. Comparison of 1 week versus 4 weeks of albendazole therapy in single small enhancing computed tomography lesion. Neurol India. 2010;58(4):560. doi:10.4103/0028-3886.68677
Apuzzo MLJ, Dobkin WR, Zee CS, Chan JC, Giannotta SL, Weiss MH. Surgical considerations in treatment of intraventricular cysticercosis: An analysis of 45 cases. J Neurosurg. 1984;60(2):400-407. doi:10.3171/jns.1984.60.2.0400
Hamamoto Filho PT, Zanini MA, Fleury A. Hydrocephalus in Neurocysticercosis: Challenges for Clinical Practice and Basic Research Perspectives. World Neurosurg. 2019;126:264-271. doi:10.1016/j.wneu.2019.03.071
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 John Vargas-Urbina, Raúl Martinez-Silva, Fernando Palacios-Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
